Our results continued a strong growth trajectory in 2023, supported by our people and commitment to providing innovative treatments for patients suffering from diseases within neuroscience, managed by specialists. Our future focus is investing for long-term sustainable growth.

Over the last couple of years, we have taken significant strides to expand our operating space through the acquisitions of Abide and Alder in 2019 and the 2021 partnering with AprilBio on the CD40L blocker, which gave us the platforms needed to expand our areas of focus in neuroscience. With the 2020 launch of Vyepti® in the U.S. and the global roll-out to many more markets globally through 2021-2023, we are establishing a new frontier in migraine prevention for the patients that need it the most. The expansion into the migraine space also provides a commercial platform for future growth into specialty neurology.

Furthermore, we have strengthened our R&D capabilities to enable us to broaden our focus in four biologies and ensure that we de-risk our internal pipeline compounds in early development.

We utilize an experimental medicine approach to identify the effects of a drug in carefully selected patient populations, to find the most efficient clinical pathway powered by biomarkers and study designs and advance the most promising drug candidates into full development. 

The geographical expansion of Vyepti® and the continuing efforts to grow and expand strategic brands, along with several other life cycle management projects, are all crucial to our future. We are also committed to pursue a programmatic approach to M&A deals to boost innovation and growth in the mid-term and to invest further in enhanced R&D productivity to drive the next decade of growth.

In 2023, we have continued to make strides in our sustainability efforts. Our most important contribution to sustainable development remains providing health to people – with a clear positive impact on local communities and society as a whole.